Evolus Added to NASDAQ Biotechnology Index
Evolus, Inc. (EOLS)
Last evolus, inc. earnings: 2/25 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
us.evolis.com/investor-relations
Company Research
Source: GlobeNewswire
IRVINE, Calif., Dec. 19, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a company dedicated to aesthetic medicine, today announced that the company has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI). The addition will become effective prior to the market open on Monday, December 24, 2018. The Nasdaq Biotechnology Index (NBI) is designed to track the performance of a set of NASDAQ-listed securities that meet certain eligibility criteria and are classified as either biotechnology or pharmaceuticals, according to the Industry Classification Benchmark (ICB). These requirements include minimum market capitalization and average daily trading volume. The NBI is ranked annually and forms the basis for a number of Exchange Traded Funds (ETFs), including the iShares Nasdaq Biotechnology ETF. For more information about the Nasdaq Biotechnology Index visit https://indexes.nasdaqomx.com. About Evolus, Inc. Evolus is a company dedicated to aesthetic medicine f
Show less
Read more
Impact Snapshot
Event Time:
EOLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EOLS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EOLS alerts
High impacting Evolus, Inc. news events
Weekly update
A roundup of the hottest topics
EOLS
News
- Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Evolus’ Sandra Beaver Named Orange County Business Journal’s Public Company CFO of the YearBusiness Wire
- Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.MarketBeat
- Evolus, Inc. (NASDAQ:EOLS) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.MarketBeat
EOLS
Earnings
- 5/7/24 - Miss
EOLS
Sec Filings
- 5/7/24 - Form 10-Q
- 5/7/24 - Form 8-K
- 4/26/24 - Form DEFA14A
- EOLS's page on the SEC website